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Background & Aims: The suppressor of cytokine signal-
ing (SOCS) proteins are a family of Src homology 2
domain-containing proteins. Currently, there are 8 mem-
bers of the SOCS family, of which a number have been
implicated strongly in the negative regulation of cyto-
kine signal transduction pathways. Methods: This review
focuses on recent discoveries about 4 SOCS family
members, SOCS-1, -2, and -3, and cytokine-inducible
SH2-domain containing (CIS), and provides more limited
information about other SOCS family members. Results:
A large number of cytokines and growth factors are now
known to induce SOCS proteins. In turn, SOCS inhibit the
actions of a growing number of cytokines and growth
factors in vitro or in vivo. SOCS proteins exert their
inhibitory effects at the level of activation of janus ki-
nases (JAKs) or by competing with transcription factors
for binding sites on activated cytokine receptors. SOCS
proteins also may mediate the ubiquitination and sub-
sequent degradation of the SOCS protein and its bound
signaling complex. Genetic modification of SOCS genes
in mice has revealed crucial roles in the negative regu-
lation of a number of important physiologic parameters
including interferon  activity, growth, blood cell produc-
tion, and placental development. Conclusions: Informa-
tion about SOCS action in gastrointestinal function and
disease is only just emerging, but available data indicate
a role in growth of gastrointestinal tissues, inflammatory
bowel disease, and cancer.
Cytokines are key mediators of appropriate physio-logic functions within the gastrointestinal tract and
accessory organs such as the liver and pancreas. The
4-helix bundle family of cytokines includes interferon
(IFN)-, many interleukins (ILs), growth hormones
(GHs), the colony stimulating factors, erythropoietin
(EPO), and leukemia inhibitory factor (LIF). The pheno-
types of a number of transgenic and gene knockout
models have emphasized the dramatic role cytokines play
in gastrointestinal function. For example, several mouse
models of spontaneous inflammatory bowel disease (IBD)
exhibit overproduction of T-helper (Th) cell–derived
cytokines such as the Th-1–derived cytokine IFN-,1–4
or the Th-2–derived cytokine IL-4.5–8 Widespread over-
expression of GH leads to overgrowth of the small and
large intestines9,10 and overgrowth and neoplastic
changes in liver and spleen.11,12 Overexpression of IL-6 in
transgenic mice leads to plasma cell hyperproliferation
and plasmacytoma,13 whereas co-overexpression of a sol-
uble IL-6 receptor in the IL-6 transgenics leads to hep-
atocellular hyperplasia and accelerated plasmacytoma de-
velopment.14 Other IL-6 transgenic lines show body
growth retardation and reduced levels of circulating in-
sulin-like growth factor I (IGF-I).15 Clearly, cytokine
action must be regulated tightly to prevent pathophys-
iological consequences.
Research in the past decade has led to major advances
in our understanding of the pathways by which cytokines
activate target cells (Figure 1). Each cytokine binds to a
specific receptor that spans target cell membranes and
induces dimerization or oligomerization, causing confor-
mational changes in receptor structure. These receptor
modifications allow for the recruitment of janus kinases
( JAKs), enzymes that bind to the receptors and phos-
phorylate specific tyrosine residues on themselves and on
the intracellular portion of the receptors. Tyrosine phos-
phorylated receptors then serve as docking sites for sig-
naling proteins that contain Src homology 2 (SH2) do-
mains or phosphotyrosine binding domains. Such
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transducers and activators of transcription; Th, T helper.




signaling proteins include RAS and phosphatidylinositol
3-kinase that, as well as being activated by cytokine
receptors, also are associated with signal transduction by
receptor tyrosine kinases that mediate the actions of
growth factors such as the epidermal growth factor or
IGFs. In addition, a family of transcription factors known
as the signal transducers and activators of transcription
(STATs) bind to activated cytokine receptors via SH2
domains and are key mediators of cytokine action. Once
bound, the STATs themselves become a substrate target
of the JAKs and are phosphorylated on key tyrosine
residues. Activated STATs disassociate from the receptor
and form homo- or heterodimers with other STAT mol-
ecules. These paired molecules cross the nuclear mem-
brane and bind to DNA sequences in the promoter
regions of target genes that are selective for particular
STAT family members and mediate the transcription of
cytokine-regulated genes.
Although our understanding of the intracellular sig-
naling molecules that mediate the functional outcome of
cytokine-receptor activation has increased profoundly,
more recent research has placed increasing emphasis on
the mechanisms by which cytokine signals are termi-
nated. The first group of molecules implicated as nega-
tive modulators of cytokine signaling were phosphatases.
Phosphatases such as signal transducers and activators of
transcription (SHP-1) dephosphorylate cytokine recep-
tors and JAKs, leading to termination of phosphoryla-
tion-dependent signaling cascades.16 The cell surface
marker CD45 also has phosphatase activity and has been
shown to regulate cytokine signaling by its ability to
dephosphorylate JAKs.17 The protein inhibitor of acti-
vated STAT proteins form a second and distinct family of
molecules capable of inhibiting a number of cytokine
pathways by their ability to bind and prevent activated
Figure 2. Schematic of SOCS box containing proteins. The SOCS
proteins are paired based on the highest amino acid homologies. The
domain structures of each molecule is detailed.
Figure 1. Cytokines bind to
specific sites on the extra-
cellular domains of their cogni-
tive receptor, causing receptor
dimerization. This allows the re-
cruitment of JAKs to the recep-
tors, which then cross-phos-
phorylate each other before
phosphorylating the receptor
on key tyrosine residues. STAT
molecules bind to these phos-
phorylated docking sites, are in
turn phosphorylated, dimerize,
and enter the nucleus where
they initiate transcription. Some
of the genes transcribed by
these factors include the SOCS
genes. The SOCS proteins then
act to negatively regulate acti-
vated receptor complexes by in-
activating JAKs or blocking re-
cruitment sites for STATs and
also may target signaling com-
plexes for ubiquitination and
degradation.
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STAT protein dimers from entering the nucleus to ini-
tiate transcription.18,19 A third family, and the topic of
this article, is composed of the suppressors of cytokine
signaling (SOCS), which have been shown to be impor-
tant physiologic regulators of cytokine signaling.
Discovery
The first member of the SOCS family of proteins
to be discovered was called cytokine-inducible SH2-
domain containing (CIS) protein. CIS was found in a
screen for negative regulators of IL-3 and EPO signal-
ing.20 Subsequent investigations using a number of
methods detected a different but homologous protein
called SOCS-1. SOCS-1 was discovered based on its
ability to inhibit IL-6–mediated differentiation of the
myeloid leukemia M1 cells into macrophages.21 SOCS-1
also was detected in a yeast 2-hybrid screen for proteins
capable of interacting with the kinase domain of JAK222
and by screening an expression library with antibodies
directed against the SH2 domain of STAT3.23 Given its
discovery by different lines of investigation, SOCS-1 has
also been termed JAK binding protein, or STAT-in-
duced STAT inhibitor. Subsequent scans of genomic and
expressed sequence tag databases revealed that CIS and
SOCS-1 proteins were part of a larger family of 8 proteins
(CIS and SOCS-1 through SOCS-7). As shown in Figure
2, each family member possesses a central SH2 domain
and a conserved motif at the C-terminus called a SOCS-
box, whereas the N-terminal regions of SOCS proteins
have variable length and sequence homology.21,24–26 Fur-
thermore, a large number of other proteins contain a
SOCS box but lack an SH2 domain. These SOCS-related
proteins can be grouped based on the presence of homol-
ogous motifs within their N-terminal regions that in-
clude ankyrin repeats, WD-40 repeats, SPRY domains,
and guanosine triphosphatase–like domains (Figure 2).24
Mechanisms of Suppressors of Cytokine
Signaling Induction and Action
Much research has documented that SOCS pro-
teins are induced by cytokines that use JAK/STAT sig-
naling pathways (Figure 1). STATs are proposed as the
direct mediators of SOCS induction, and SOCS in turn
inhibit JAK kinase activation or the ability of JAKs to
activate STATS, thus forming a classic negative feedback
mechanism (Figure 1). In addition, considerable evidence
supports a concept that one or more SOCS proteins may
act to limit the duration of cytokine signaling by serving
as adaptor molecules to link active signaling complexes
with degradation pathways. Ubiquitin-dependent pro-
teasome-mediated degradation is a major intracellular
pathway by which membrane-associated proteins are de-
graded. This proteasome-degradation complex involves a
number of proteins including ubiquitin ligases, elongins,
and cullin-2. It is hypothesized that the SOCS proteins
and/or their bound signaling complexes become targets
for ubiquitination, and subsequently are degraded by the
proteasome. Evidence in support of the concept stems
from findings that a number of the SOCS, and SOCS-box
containing, proteins bind to elongin B and C, which in
turn bind E3 ubiquitin ligase and cullin-2.27,28
As well as induction by cytokines that use JAK-STAT
signaling pathways, it increasingly is clear that SOCS
proteins are induced via STAT-independent mechanisms
including stimuli such as stem cell factor,29 lipopolysac-
charide,30 and methylated DNA.31 Transcription factors
that mediate STAT-independent SOCS induction are not
well defined. SOCS mRNAs are expressed constitutively
in multiple cell types and numerous tissues throughout
the body including the gastrointestinal tract, liver, and
pancreas (Miller, unpublished data, 2002),21,26,32–35 but
their expression is enhanced greatly by cytokines. The
time course and duration of SOCS induction vary de-
pending on the particular cytokine or SOCS protein as
discussed in more detail later. The scope of the potential
modulatory actions of SOCS is shown in Table 1, which
summarizes much of the available information generated
from initial in vivo and in vitro experiments about which
cytokine pathways induce each SOCS protein and which
cytokine pathways are inhibited by particular SOCS pro-
teins. More detailed information is available now about
SOCS-1, SOCS-2, SOCS-3, and CIS and this is reviewed
later, as well as the more limited information about other
SOCS family members. As yet, relatively little is known
about the function of SOCS in the gastrointestinal tract
but some published and preliminary findings support the
concept that SOCS play a role in the regulation of growth




SOCS-1 mRNA is induced by and inhibits a
variety of cytokines, including IFNs, IL-4, IL-6, LIF, and
EPO in vitro or in vivo (Table 1). Cytokine induction of
SOCS-1 mRNA generally is rapid and transient, with
detectable induction within 15 minutes, peak induction
at 2 hours, and reversion to baseline by 4 hours. SOCS-1
inhibits cytokine action by inhibiting JAK activation in
vitro or in vivo. The SH2 domain of SOCS-1 is thought
to be a key mediator of JAK inhibition because it binds
to the kinase domain of JAK2.22 Phosphopeptide bind-
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ing studies suggest that SOCS-1 inhibits JAK2 by bind-
ing to a key tyrosine (Tyr-1007) in the activation loop of
its kinase domain,36 thereby supporting a model in
which SOCS-1 inhibits cytokine signaling by binding to
the activation loop of JAK-2 and restricting access of
other substrates to JAK-dependent phosphorylation and
activation. Structure function studies defined the SH2
domain and 30 amino acids of the adjacent N-terminal
region of SOCS-1 (called the kinase inhibitory region) as
essential for SOCS-1 inhibition of IL-6 signaling. The
entire N-terminal domains of SOCS-1 and SOCS-3 ap-
pear to be interchangeable in terms of their ability to
inhibit signaling by LIF, which implies that SOCS-1 and
SOCS-3 may have a shared or overlapping mechanism of
inhibiting the actions of some cytokines.37
As well as JAK inhibition, there is considerable evi-
dence that SOCS-1 mediates proteasomal degradation of
a number of signaling proteins. SOCS-1 binds to the
hematopoietic-specific guanine nucleotide exchange fac-
tor, VAV, and targets it for ubiquitin-mediated protein
degradation.38 The conserved C-terminal SOCS-box mo-
tif appears to mediate SOCS interaction with compo-
nents of the proteasomal degradation machinery,27,28
even though the SOCS box may protect the SOCS pro-
tein itself from degradation39 and is dispensable for
cytokine signaling inhibition in overexpression sys-
tems.36,37,39 The strength of the argument that the SOCS
box mediates degradation of signaling complexes re-
cently has gained more credence with a number of stud-
ies showing a role for SOCS-1 in the regulation of the
TEL-JAK oncogene, which is associated with human
leukemia. The TEL-JAK protein is a fusion protein
caused by a chromosomal translocation from the 5 end
of the TEL gene on 12p13 to the 3 end of JAK2 on
9p24 and is observed in some human lymphomas. Trans-
fection of TEL-JAK expression constructs into Ba/F3
cells leads to cytokine-independent proliferation caused
by hyperactivation of JAKs and STAT5.40 Enforced over-
expression of SOCS-1 blocks JAK activity and reduces
the level of TEL-JAK expression.41 Additionally, the
SOCS box of SOCS-1 interacts with cullin-2 and
promotes ubiquitination of TEL-JAK2, whereas over-
expression of dominant-negative cullin-2 suppresses
SOCS-1–dependent TEL-JAK2 degradation.42 The bio-
logic significance of this observation was shown by the
finding that transplantation of murine bone marrow with
retroviral constructs expressing both TEL-JAK2 and
SOCS-1 prolongs the latency of disease and death com-
pared with those expressing TEL-JAK2 alone.43 The
phenotype of SOCS-1‚/‚ mice, which lack only the
SOCS box of SOCS-1 also supports an important role for
this motif in SOCS-1 action (see later).44
Mice devoid of SOCS-1 (SOCS-1/ mice) have pro-
vided significant insight into the physiologic role(s) of
this cytokine suppressor and validated the large amount
of previously generated in vitro data. SOCS-1/ mice
are born healthy and in expected Mendelian proportions,
but die before weaning from a complex hematologic and
pathologic phenotype.45,46 Histologic examination re-
vealed that SOCS-1/mice exhibited fatty degeneration
and necrosis of the liver, significant depletion of T- and
B-lymphocyte numbers, deficits in the number of lym-
Table 1. SOCS Proteins Are Induced, Inhibited, and Associated With a Range of Growth Factor and Cytokine Signaling









CIS IL-2,21,23,120 IL-3,20,120 IL-6,21 IL-9,133 IFN-,134 TNF-,135
EPO,20,120 LIF,21 leptin,136 GH,35,78,137,138 OSM,120
TSLP,139 prolactin68





SOCS-1 IL-6,21,52,109 IL-7,57 IL-1321 IFN,69,141–144 G-CSF,21










SOCS-2 IL-6,21 IL-9,133 IFN-,134 IFN-,154 LIF,21 GH,35,78,137
prolactin,68 insulin155
GH,85,87 IL-6,21 IGF-I88 IGF-I receptor,88 GH receptor,83,85
prolactin receptor 68
SOCS-3 IL-1,156 IL-2,32 IL-6,21 IL-9,133 IL-10,157,158 IL-13,21
IFN-,134 IFN-,144 GM-CSF,25 EPO,21,25 LIF,21,25,26,159
CNTF,146 Leptin,160,161 insulin,155,162 cardiotrophin,147
GH,35,78,137 prolactin68
EPO,51,108 IL-2,32 IL-3,32 IL-4,63,148
IL-6,37 IL-9,133 IL-11,163 LIF,21,25
IFN,144 GH,78,83,85 prolactin,67–69
leptin,160 insulin,162 IGF-I164
GH receptor,83,85 IGF-I receptor,164
gp130,110,111 leptin receptor,165
Lck,25 FGF receptor,25 PYK225
SOCS-4 Unknown Unknown Unknown
SOCS-5 IL-624 IL-637 Unknown
SOCS-6 Unknown Unknown Insulin receptor127
SOCS-7 Unknown Unknown Ash,129 PLC ,129 Nck129
TNF, tumor necrosis factor; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; M-CSF,
macrophage colony stimulating factor; TPO, thrombopoietin; CNTF, cilliary neurotrophic factor; PKC, protein kinase C; PLC, phospholipase C.
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phoid follicles, and extensive macrophage infiltration in
the liver, pancreas, heart, and lung.46 The gut, bladder,
kidney, and gonads of SOCS-1/ mice are grossly nor-
mal, although these mice do suffer reduced thymus
weight and lower thymic and splenic T-cell numbers,
which has been postulated to reflect accelerated T-cell
apoptosis.45 The important role of SOCS-1 in regulating
the immune response to infection was emphasized by the
findings that SOCS-1/ mice are hyperresistant to Sem-
liki forest virus, and IFN-–treated bone marrow mac-
rophages from SOCS-1/ mice have a greatly enhanced
capacity to kill Leishmania major.47
The phenotypic characteristics of SOCS-1/ mice
have striking similarity to those observed in neonatal
mice injected with IFNs,48 raising the possibility that
SOCS-1/ mice suffer from deregulated production or
responsiveness to IFNs. Consistent with this possibility,
SOCS-1/ mice have more activated STAT1, a primary
mediator of IFN action, and increased expression of
STAT1-responsive genes.47 SOCS-1/ IFN-/ dou-
ble knockout mice survive weaning and are healthy until
at least 6 months of age.47 The pathology associated with
absolute SOCS-1 deficiency also can be prevented by
giving SOCS-1/ mice twice-weekly injections of anti-
bodies against IFN-. Together, these in vivo findings
provide compelling evidence that SOCS-1 limits IFN
action. SOCS-1/ IFN-/ mice are more acutely sen-
sitive to IFN- injections and have more prolonged
STAT1 phosphorylation in response to IFN- compared
with IFN-/ mice.49 Interestingly, although SOCS-
1/ IFN-/ mice appear normal from birth to adult-
hood, abnormalities appear later in life, characterized by
polymyositis and myocarditis that kills all mice by 160
days of age.50
SOCS-1‚/‚ mice, which lack only the SOCS box of
SOCS-1, are born healthy but die prematurely of a
complex histopathologic disease similar to that of SOCS-
1/ mice, although the onset of the disease phenotype
and eventual mortality is delayed in SOCS-1‚/‚ mice.44
This intermediate phenotype provides strong support
that the SOCS box is necessary for appropriate timing,
duration, or magnitude of cytokine inhibition by
SOCS-1, presumably by mediating proteasome degrada-
tion of SOCS-1–associated cytokine receptor signaling
complexes. Direct evidence that the SOCS box of
SOCS-1 plays an important role in SOCS-1 regulation of
IFN- signaling derives from findings that IFN-–in-
duced STAT1 activation is prolonged in SOCS-1‚/‚
hepatocytes compared with wild-type cells, but is not as
extended as in SOCS-1/ hepatocytes.44
The concept that the SOCS-1/ phenotype is ex-
plained by hyperresponsiveness to IFN- may be only
part of the story because these mice also have elevated
levels of IFN-.51 The cellular sites of this IFN- over-
production and the exact sites where absolute SOCS-1
deficiency leads to deregulated IFN- action are yet to be
conclusively defined, but available evidence indicates
deregulation of Th-1 cells. Diehl et al.52 reported find-
ings that suggest that SOCS-1 mediates IL-6 inhibition
of Th-1 cell differentiation. Consequently, a lack of
SOCS-1 could allow for enhanced Th-1 differentiation
and Th-1 cells could be responsible for the increased
IFN- expression in SOCS-1/ mice.52 JAK3-deficient
mice suffer from B- and T-cell lymphopenia and signif-
icantly depleted thymocyte populations.53–55 When
JAK3-deficient mice are reconstituted with bone marrow
from SOCS-1/ mice they develop the same disease
phenotype as observed in SOCS-1/ mice.56 This sup-
ports a concept that lymphocyte or myeloid cells from
SOCS-1/ mice can mediate expansion of IFN-–pro-
ducing lymphocytes. The hypothesis that lymphocytes
are the major source of the disease in SOCS-1/ mice
also was examined by crossing recombination activating
gene (RAG)-2/mice and SOCS-1/mice. RAG-2/
mice suffer from a lack of B and T cells owing to
defective B- and T-cell receptor rearrangement, and so
are not susceptible to disease mediated by activated B or
T cells. SOCS-1/ RAG-2/ mice have a longer life-
span than SOCS-1/ mice, providing strong evidence
that T cells and/or B cells contribute to the abnormalities
in SOCS-1/ mice.56
Examination of transgenic mice that overexpress
SOCS-1 in their T cells confirms many of the conclusions
obtained in SOCS-1 null mice and also shows impaired
responses to IL-6 and IL-7.57
Emerging evidence suggests that SOCS-1 may inte-
grate the interactions between IFN- and IL-4.58,59 This
may be relevant especially to better understanding of the
pathophysiology of Crohn’s disease (CD) and ulcerative
colitis (UC), which are associated with a predominance of
IFN-–producing Th-1 cells and IL-4–producing Th-2
cells, respectively.60 IFN-, a Th-1–derived cytokine, is
known to antagonize the actions of IL-4 by repressing the
expression of a number of IL-4–induced genes including
15 lipoxygenase and IL-1–receptor antagonist.61,62 In-
triguingly, neither the 15 lipoxygenase nor IL-1–recep-
tor antagonist genes contain a classic IFN- responsive
gamma activated sequence within their promoters; a
DNA response element that mediates IFN- action by
binding STAT1. These genes do, however, contain a
STAT6 binding element that generally mediates the
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transcriptional effects of IL-4.58 By using cultured hu-
man monocytes, Dickensheets et al.59 found that pre-
treatment of cells with IFN- but not IL-1, IL-2, G-
colony stimulating factor, IL-6, or transforming growth
factor  suppresses the ability of IL-4 to activate STAT6.
This inhibitory effect of IFN- correlates temporally
with induction of SOCS-1. They also showed that forced
expression of SOCS-1 in RAW264 macrophages sup-
pressed transcriptional activation of IL-4–induced re-
porter genes59 as has been observed in other cell lines.63
The intriguing possibility that SOCS-1 may mediate the
interplay between IFN- and IL-4 is further supported
by recent in vivo studies by Naka et al.64 They found that
IL-4 injections accelerate disease development in SOCS-
1/ mice, whereas deletion of STAT1 or STAT6 genes
improves disease pathologies.64 They also found that the
hyperactivity of the IFN- and IL-4 signaling systems in
SOCS-1/ mice caused abnormal activation of natural
killer T cells that appeared to mediate much of the
degenerative liver pathology.64 Recent studies suggested
that SOCS-1 predominates in mouse-derived Th-1 cells
and limited IL-4 action in these cells,65 further support-
ing the concept that SOCS-1 has a key role in Th-1 cell
differentiation and selective cytokine responsiveness. Fu-
ture studies of SOCS-1 regulation of IFN-/IL-4 actions
and interactions in animal models of IBD, and in specific
immune cell subtypes derived from animal models and
patients with IBD, should lead to new insights into
mechanisms that underlie aberrant or dysregulated T-cell
responses in UC or CD.
SOCS-1 appears to have physiologic roles outside the
hematopoietic compartment. SOCS-1/ mice exhibit
low blood glucose levels and have sustained insulin-
induced phosphorylation of insulin-receptor substrate-1,
indicating inhibitory effects of SOCS-1 on insulin sig-
naling.66 SOCS-1 inhibits prolactin signaling in
vitro67–69 and inhibits the in vivo effects of prolactin on
mammary gland development. SOCS-1/ IFN-/
mice show accelerated lobualveolar development, in-
creased milk protein gene expression, and higher levels of
phosphorylated STAT5 at day 18 of pregnancy. Deletion
of one SOCS-1 allele is capable of rescuing a lactogenic
defect in mice lacking one allele of the prolactin receptor,
which clearly implicates SOCS-1 as a dose-dependent,
negative regulator of prolactin signal transduction.70
Gene dosage effects of SOCS-1 on prolactin receptor
signaling raise the important possibility that relatively
small quantitative differences in expression of SOCS-1,
or other SOCS, may lead to aberrant cytokine action that
could in turn underlie disease susceptibility or severity.
Heterozygote mouse models with targeted disruption of
one SOCS allele could prove useful to delineate the
consequences of quantitative differences in SOCS expres-
sion for cytokine action on growth, function, or disease in
gastrointestinal tissues.
Given the role that cytokine signaling plays in devel-
opment and control of cell growth it is perhaps not
surprising that SOCS-1 has been implicated as a tumor
suppressor. Two groups have shown recently that the
CpG islands within the SOCS-1 gene are methylated in a
large proportion of human hepatocarcinomas, which re-
sults in silencing of SOCS-1 expression and constitutive
JAK activation.71,72 Re-introducing SOCS-1 back into
hepatocellular carcinoma cells is sufficient to reduce their
growth rate and inhibit anchorage-independent growth.
These findings implicate constitutive activation of the
JAK/STAT pathway as a key factor in the development
of hepatocellular carcinoma. The tumor suppressor activ-
ity of SOCS-1 warrants further investigation as a poten-
tially important factor in susceptibility in cancer of other
gastrointestinal tissues such as the colon or pancreas.
Although low-level, constitutive expression of
SOCS-1 has been reported in small and large intestines of
humans and rodents,26,33,34 the cellular sites of SOCS-1
expression in intestines in vivo have not been defined.
Given the apparent role of SOCS-1 in integrating IL-4
and IFN- action, more detailed studies of the levels and
sites of SOCS-1 expression in intestines of IBD patients
and animal models of IBD are warranted. One published
report73 and our preliminary findings33 do not show
altered expression of SOCS-1 mRNA in resected, dis-
eased intestines from patients with UC or CD compared
with nondiseased controls, or in the intestines of a num-
ber of animal models of IBD.33,73 However, in these
studies, SOCS-1 expression was analyzed in total RNA
extracted from entire intestines at times when disease
was well established. Analyses of SOCS-1 at different
phases of disease and in isolated subpopulations of cells
such as intraepithelial or lamina propria lymphocytes, or
epithelial cells, are required to definitively establish if
SOCS-1 expression changes in the intestine during the
course of IBD. Recent, preliminary studies indicate that
SOCS-1 is expressed in lamina propria monocytes from
patients with IBD.74 It is important to point out that
much of our information to date about SOCS-1 expres-
sion, especially in cells or tissues in vivo, is at the mRNA
level. Levels of expression of SOCS-1 are, however, sub-
ject to regulation at the level of translation, where in-
frame AUG codons within the 5 untranslated region
permit translational repression.75,76 Recent studies have
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revealed that the Pim family of serine/threonine kinases
regulate the stability of SOCS-1 such that Pim-mediated
phosphorylation stabilizes SOCS-1/ and Pim/ mice
show reduced levels of SOCS-1.77 Thus, it will be essen-
tial to examine SOCS-1 expression at the protein as well
as mRNA level to fully define its sites and levels of
expression in normal or diseased gastrointestinal tissues.
Suppressors of Cytokine
Signaling 2
Compared with SOCS-1, fewer cytokines induce
SOCS-2 and these include GH and prolactin (Table 1).
On cytokine exposure in vivo or in vitro, initial low
levels of SOCS-2 expression climb steadily over a period
of 8 hours or longer,35,78 which contrasts with the rapid,
more transient mRNA induction observed for SOCS-1
and other SOCS such as SOCS-3. Initial studies exam-
ined whether SOCS-2, like SOCS-1, modulates cytokine
action in M1 cells. SOCS-2 overexpression caused only a
partial inhibition of IL-6 signaling, which contrasts with
the more potent inhibition by SOCS-1.37 No inhibitory
effects of SOCS-2 overexpression have been noted in most
hematopoietic cytokine assay systems, implying a lim-
ited role of SOCS-2 in immune function. Exceptions are
chronic myeloid leukemia cells with Bcr-Abl mutation
that show elevated SOC-2 expression.79 Forced overex-
pression of SOCS-2 in these cells reduces growth and
increases sensitivity to antagonists of the Bcr-Abl ty-
rosine kinase.79
A number of lines of evidence suggest that SOCS-2
may have a particular role in regulating the actions of
GH. GH has a well-established role in mediating so-
matic and skeletal growth in the postnatal period as well
as proportionate growth of many organs including the
liver and small and large intestine.80 Many, but not all,
of the growth-promoting actions of GH are mediated by
circulating IGF-I, which derives largely from hepato-
cytes81 and by IGF-I, which is expressed in mesenchymal
cells within nonhepatic tissues.80,81 It recently has been
shown that STAT5b is a key mediator of GH-induced
IGF-I expression in the liver.82 SOCS-2 binds to gluta-
thione-S-transferase–GH–receptor fusion proteins in a
phosphorylation-dependent manner and binds to a re-
gion of the intracellular domain of the GH receptor that
contains 3 postulated STAT5 binding sites.83–85 SOCS-2
overexpression experiments performed by Ram andWax-
man85 indicate that SOCS-2 decreases STAT5 activation
in response to GH. These data support a concept that
SOCS-2 may regulate GH-dependent transcriptional in-
duction of the IGF-I gene, or other STAT5b responsive
genes. Although these data suggest an inhibitory role of
SOCS-2 on GH action, some initial observations para-
doxically indicated that SOCS-2 overexpression enhances
the activity of STAT5 reporter genes.78,83,86 It has been
suggested that these dual actions of SOCS-2 may be
determined by the levels of expressed SOCS-2 and the
possibility that SOCS-2 may attenuate the actions of
SOCS family members with more potent inhibitory ca-
pabilities.79,86 Consistent with this concept, the decrease
in GH-dependent STAT5 activation that results from
SOCS-2 overexpression is not as dramatic as the complete
suppression observed when SOCS-1 and SOCS-3 are
overexpressed.85,87 Defining the physiologic role of
SOCS-2 has been complicated further by evidence that
SOCS-2 interacts with the IGF-I receptor, as well as the
GH receptor. Yeast 2-hybrid assays found that SOCS-2
interacts with the intracellular tail of the IGF-I receptor,
and biochemical studies revealed that GST-SOCS-2 fu-
sion proteins bind to activated IGF-I receptor.88 Further-
more, FLAG epitope-tagged hSOCS-2 co-immunopre-
cipitates with active IGF-I receptor in transiently
transfected cell lines.88 There currently is no evidence
that IGF-I is capable of inducing SOCS-2 expression, but
these findings imply that SOCS-2, induced by GH or
other cytokines, could alter IGF-I as well as GH action.
The phenotype of SOCS-2/ mice provides consider-
able evidence that SOCS-2 plays an important in vivo
role in GH action, and possibly the actions of IGF-I.
SOCS-2/ mice are viable and, unlike the SOCS-1/
mice, are healthy from birth to adulthood and show no
detectable abnormalities in the hematopoietic system.89
Male and female SOCS-2/ mice show a 30% to 40%
increase in body weight by 12 weeks of age that involves
significant increases in body, tail, and long-bone lengths.
The increased body weight in SOCS-2/ mice is not
owing to fat accumulation and many of the internal
organs, including the liver, are enlarged in proportion to
the increase in body size.89 Although the original anal-
yses of SOCS-2/ mice did not examine the intestine,
recent preliminary studies show an increase in weight of
the small intestine (Heath et al., unpublished observa-
tions, 2001). The growth abnormalities in SOCS-2/
mice have obvious similarities to those reported in GH-
and IGF-I–overexpressing transgenic mice,9,11,90,91 pro-
viding strong support for a hypothesis that SOCS-2
modulates GH- or IGF-I–dependent growth. Until re-
cently it was thought that circulating IGF-I was deter-
mined largely by the levels of IGF-I expression in the
liver and, specifically, hepatocytes. Hepatic levels of
IGF-I expression are highly dependent on GH.81 Unex-
pectedly, however, SOCS-2/ mice do not have detect-
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able increases in circulating IGF-I levels compared with
wild-type mice.89 SOCS-2 may therefore play a minor
role in limiting GH-dependent IGF-I expression in the
liver or, because GH induces multiple SOCS family
members in the liver,92 it is possible that they may
compensate for any effect of SOCS-2 deficiency on he-
patic IGF-I synthesis. The fact that SOCS-2/ mice
exhibit increased growth yet normal circulating IGF-I
challenges the view that circulating IGF-I is the major
determinant of postnatal body growth, as do observations
that postnatal growth is normal in mice with hepatocyte-
specific IGF-I gene deletion and 25% normal circulating
IGF-I.81 Increasingly it appears that the levels of local
IGF-I expression in nonhepatic tissues may be integral to
normal growth.81 Consistent with this concept, SOCS-
2/ mice show increased expression of IGF-I in a num-
ber of nonhepatic tissues. This may lead to organ or body
overgrowth and relate to specific or preferential up-
regulation of SOCS-2 by GH in these tissues compared
with liver. More recently, it has been discovered that the
high growth mouse, which also exhibits accelerated post-
natal growth,93 has a mutation resulting in the deletion
of the majority of the SOCS-2 coding region.94 The
phenotype of the high-growth mouse is nearly identical
to that of the SOCS-2/ mouse, except that moderately
elevated circulating IGF-I levels are detected in high-
growth mice in a time- and strain-dependent man-
ner.93–95
Distinguishing whether SOCS-2 preferentially regu-
lates either the GH or the IGF-I signaling pathway based
on the phenotype of SOCS-2/ mice is difficult. This is
because of the intertwined relationships between GH and
IGF-I, low receptor expression in most tissues, and the
difficulty in deriving primary cell lines that are GH
responsive. However, primary hepatocytes from SOCS-
2/ mice display modest prolongation of STAT5 phos-
phorylation compared with wild-type hepatocytes, and
crossing SOCS-2/ with STAT5b/ mice has revealed
that STAT5b is critical to the manifestation of the
SOCS-2 null growth phenotype.96 This provides compel-
ling evidence that altered STAT5b activation contributes
to the phenotypic consequences of absolute SOCS-2 de-
ficiency.
Our long-term interest in the enterotrophic actions of
GH and IGF-I80 led us to consider the possibility that
SOCS-2 may be an important determinant of the func-
tional outcome of GH or IGF-I action on intestinal
growth. Similar increases in mass of the small intestinal
mucosa and circulating IGF-I levels occur in transgenic
mice with widespread expression of GH9 or IGF-I.91
However, IGF-I, but not GH transgenics, show sus-
tained increases in crypt cell proliferation through adult-
hood whereas GH but not IGF-I transgenics show in-
creased sucrase activity.9,91 In a rat total parenteral
nutrition (TPN) model, systemic IGF-I had much more
potent actions on crypt cell proliferation than GH, even
though GH potently increased circulating IGF-I lev-
els.97,98 These differences led us to consider the possibil-
ity that GH may somehow limit the proliferative actions
of IGF-I on the intestine.80 This is a significant issue
because GH is one of few cytokines, if not the only
cytokine, used clinically to promote enhanced functional
capabilities in patients on long-term TPN owing to short
bowel syndrome.99–101 One concern in the clinical use of
GH in these patients is the possibility that sustained
GH-dependent increases in crypt cell proliferation could
increase susceptibility to colorectal cancer.80 Our recent
studies support the concept that SOCS-2 may serve to
limit crypt cell proliferation in response to GH or IGF-I
induced by GH as depicted in the hypothetical model in
Figure 3. In a rat TPN model, GH selectively induced
SOCS-2 but not SOCS-1, SOCS-3, or CIS, and IGF-I did
not significantly affect expression of any of the SOCS
mRNAs (Miller et al., unpublished data, 2002).34 This
selective effect of GH on SOCS-2 in the small intestine
differs from its effects in liver where SOCS-1, -2, -3, and
CIS are all induced by GH.78 It is important to point out
that TPN itself does not increase the levels of SOCS-2
expression in the intestine compared with oral feeding
(Miller et al., unpublished data, 2002)34 and we have
observed GH-dependent increases in SOCS-2 expression
in the intestine of orally fed mice (Miller and Lund,
unpublished data, 2002). Thus, it seems likely that
SOCS-2 plays a role in GH action on intestines in both
TPN-fed and orally fed animals. GH induces SOCS-2 in
Caco-2 colon cancer–derived epithelial cell lines, indi-
cating that SOCS-2 is a product of intestinal epithelial
cells. Forced overexpression of SOCS-2 in Caco-2 cells
reduces spontaneous proliferative activity and the ability
of both GH and IGF-I to stimulate Caco-2 cell prolifer-
ation (Miller et al., unpublished data, 2002).102 To-
gether, these findings suggest that SOCS-2 may have a
Figure 3. Model predicting the role of SOC-2 in GH-mediated prolifer-
ation and differentiation of intestinal epithelium. GH initially induces
IGF-I, which stimulates crypt cell proliferation, but subsequent induc-
tion of SOCS-2 prevents sustained proliferation. SOCS-2 may impact
on differentiation but this has not been examined definitively.
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particular role in limiting the magnitude or duration of
the proliferative actions of GH and IGF-I on intestinal
epithelial cells. Mechanistically, it will be important to
establish if the primary role of SOCS-2 is to prevent GH
action or to terminate its actions once initiated. Avail-
able evidence suggesting that GH-dependent activation
of STATs precedes SOCS-2 induction and the established
role of SOCS as STAT-induced feedback inhibitors of
cytokine action in other systems favor the latter possi-
bility. Ongoing studies are further evaluating SOCS-2
action in additional intestinal epithelial cell lines and in
intestines of SOCS-2/ mice to test if SOCS-2 plays a
primary role in regulating proliferation or affects differ-
entiation as well (Figure 3). It is noteworthy that the
ability of SOCS-2 to inhibit proliferation of the Caco-2
colon cancer cell line raises the possibility that SOCS-2
could have tumor-suppressive actions in colon cancer.
Together with the evidence for a similar role of SOCS-1
in hepatocellular carcinoma, this emphasizes the poten-
tial significance of these cytokine suppressors in control-
ling tumorigenesis within the gastrointestinal tract.
SOCS-2 may be relevant to potential complications of
GH therapy in patients with CD. A small, placebo-
controlled trial suggested beneficial effects of GH in
these patients103 and experimental data in animal models
of intestinal inflammation indicated beneficial actions of
GH to stimulate mucosal repair and remission of inflam-
mation.10,104 However, a potential concern is that GH
therapy could exacerbate fibrosis, a complication ob-
served in CD but not UC.105 This concern derives from
observations that increases in locally expressed IGF-I in
mesenchymal cells at sites of fibrosis are a common
feature of CD and animal models of CD.105,106 GH could
further increase IGF-I expression and fibrosis. In TPN-
fed rats, preliminary data show that GH and IGF-I both
increase collagen expression, but less potent actions of
GH correlate with GH induction of SOCS-2 at sites of
collagen synthesis.107 These preliminary findings in the
TPN model provide indirect evidence that SOCS-2 could
limit the fibrogenic complications of GH therapy in
other situations such as CD. There is in fact in vivo
evidence that SOCS-2 limits collagen accumulation in
other organs because SOCS-2/ mice show marked
thickening of the dermis owing to increased collagen
deposition and collagen accumulation in some ducts and
vessels.89 The possibility that SOCS-2 or other SOCS
limit cytokine-induced collagen accumulation warrants
further investigation because this is relevant to the in-
curable complications of fibrosis associated with chronic
injury or inflammation of gastrointestinal tissues.
Suppressors of Cytokine
Signaling 3
After SOCS-1, SOCS-3 is the most extensively
studied member of the SOCS family. SOCS-3 shares
several features in common with SOCS-1. This includes
a high degree of amino acid homology and induction by
a wide range of cytokines including IL-2, IL-3, IL-4,
IL-6, IL-10, GH, leptin, prolactin, LIF, EPO, thrombo-
poietin, IFN-, tumor necrosis factor , and insulin.
Similar to SOCS-1, SOCS-3 inhibits the actions of mul-
tiple cytokines (Table 1) and is rapidly but transiently
induced by cytokines. In addition, SOCS-3 can be im-
munoprecipitated with JAKs as observed for SOCS-1.
However, several studies indicate that in contrast to
SOCS-1, SOCS-3 has little108,109 or no effect37 on JAK
activation in vitro. Because this suggests a different
mode of action of SOCS-3 compared with SOCS-1, re-
cent studies assessed the ability of SOCS-3 to bind to
potential target phosphopeptide sequences present
within JAKs, STATs, and the common gp130 subunit
shared by a number of cytokine receptors including the
IL-6 and LIF family of cytokines. These studies revealed
that SOCS-3 has the highest affinity for the tyrosine 757
of the gp130 receptor and that mutation of the Tyr 757
residue to alanine ablates the ability of SOCS-3 to inhibit
gp130 receptor signaling.110,111 This is intriguing be-
cause Tyr 757 is also the site of interaction of SHP-2, a
phosphatase that is thought also to be a negative regu-
lator of gp130 signaling.112–114 In light of the new data
showing that SOCS-3 inhibits gp130 signaling by bind-
ing to Tyr 757, it is possible that previous reports of
negative regulation via Tyr 757 attributed to SHP-2,
may in fact be owing to the actions of SOCS-3.
Despite the evidence that SOCS-3 binds to the gp130
subunit and JAKs, the mechanisms by which SOCS-3
suppresses cytokine signaling are not yet fully defined.
Evidence that the N-terminal regions of SOCS-3 can be
substituted with that of SOCS-1 indicates that at least
this region of SOCS-3 may be involved in the binding of
JAK, but may not affect its kinase activity.37 Experimen-
tal data examining SOCS-3 suppression of EPO signaling
supports such a model in which key residues in SOCS-3
have been defined that are critical for binding the EPO
receptor and JAK.108 However, the actions of SOCS-3
may not be restricted to the termination of signaling but
could include signal modification. SOCS-3 is the only
SOCS protein known to be phosphorylated32,115 and
Cacalano et al.116 have discovered that this modification
allows SOCS-3 to inhibit STAT activity, but at the same
time enhance extracellular-signal–regulated kinase (Erk)
activity by recruiting p120 RasGAP, an important me-
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diator of Erk activation. A recent study indicated that
deletion of the STAT3 binding site in the gp130 recep-
tor leads to impaired induction of SOCS-3 and SOCS-2,
and mice with this mutation show gastric ulceration, and
sustained SHP-2–mediated Ras/Erk activation.117 This
suggests that SOCS may mediate reciprocal cross-talk
between SHP-2/Erk activation and STAT activation.
The gastric ulceration phenotype in these mice indi-
cates that normal STAT and SOCS expression or the
balance between STAT and SHP-2/Erk activation may
be highly relevant to normal mucosal integrity in the
stomach.
SOCS-3–deficient mice have been generated and are
reported to die in utero between E12 and E16 owing to
marked erythrocytosis around the liver and in the ab-
dominal region. Colony assays of hematopoietic progen-
itor cells from E12–E16 SOCS-3/ embryos also re-
vealed that IL-3/EPO-stimulated blood forming unit–E
and colony forming unit–mix colonies were significantly
larger than those derived from wild-type cells. Further-
more, fetal liver erythropoiesis was suppressed com-
pletely when SOCS-3 was transgenically overexpressed in
embryos.51 Together these results strongly support ini-
tial overexpression studies implicating SOCS-3 as a key
regulator of EPO signaling.108 A more recent study
characterized an independently generated SOCS-3/
mouse and found that these mice die in utero between
E11–E13. In contrast to the previous results, these
SOCS-3/ mice do not suffer from erythrocytosis and
have no major defects in hematopoiesis or erythropoiesis
in a variety of assays.118 However, these mice do display
placental defects at E10.5, which would most likely
account for the small size of SOCS-3/ embryos com-
pared with wild-type embryos and may have contributed
to their mortality. Examination of SOCS-3 pre- and
postnatal function is hampered by embryonic mortality,
but it is hoped that the adoption of other technologies,
such as cell-specific, Cre/lox-mediated gene disruption
will bypass this impediment.
The importance of SOCS, specifically SOCS-3, to in-
flammatory processes in the intestine has been brought to
light by recent studies in patients with IBD and in
animal models of IBD. Inflamed colon samples from
patients with UC or CD and from multiple mouse mod-
els of spontaneous or inducible T-cell mediated colitis all
exhibit elevated levels of SOCS-3.33,73 The animal mod-
els include IL-10/ mice, mice with macrophage-spe-
cific STAT-3 deletion, T-cell receptor  chain–deficient
mice, mice with colitis induced by trinitrobenzene-sul-
fonic acid or sodium dextran sulfate (DSS)-induced coli-
tis, and rats with enterocolitis induced by peptidoglycan
polysaccharides. The DSS colitis model is one of acute
mucosal injury and inflammation followed by mucosal
repair when DSS is withdrawn. In this model, SOCS-3
mRNA expression is highest after withdrawal of DSS,
indicating a potential role in mucosal repair or remission
of inflammation.33,73 SOCS-3 mRNA expression during
DSS-induced intestinal inflammation localized largely to
the mucosa in hyperplastic epithelial cells and lamina
propria cells that may be immune cells or mesenchymal
cells or both.33,73 Particularly intense up-regulation of
SOCS-3 occurs at sites of mucosal ulceration.33 Although
2 studies suggest that SOCS-3 is preferentially up-reg-
ulated in IBD and animal models of IBD compared with
SOCS-1, SOCS-2, or CIS, it is important to consider the
limitations in detection of changes in RNA or protein
expression is small subpopulations of cells when analyz-
ing whole tissues. It will be important, therefore, to
perform additional analyses of other SOCS family mem-
bers as well as SOCS-3 at the cellular level. Localization
of SOCS-3 to epithelial cells in animal models of
IBD33,73 and to hyperplastic epithelial cells73 and sites of
ulceration33 raises the intriguing possibility that SOCS-3
may play a role in either mucosal restitution or in
limiting the magnitude or duration of crypt hyperpro-
liferation that accompanies mucosal repair. It is difficult
at this point to directly test the role of SOCS-3 in
intestinal inflammation in vivo without viable adult
SOCS-3 knockout or transgenic animals. However, trans-
genic mice engineered to express low levels of SOCS-1
and -3 proteins containing a point mutation in the kinase
inhibitory region do exhibit signs of more severe DSS-
induced colitis than wild-type mice, including more
severe weight loss, epithelial hyperplasia, goblet cell
depletion, and increased STAT-3 activation.73 Because
the level of phosphorylated STAT-3 correlates qualita-
tively with the severity of colitis across the mouse mod-
els,73 this evidence that SOCS-3 inhibits STAT-3 acti-
vation indicates a protective role during intestinal
inflammation. Nonetheless, additional studies are re-
quired to precisely define the role of SOCS-3 in different
models of IBD and in repair after inflammation-induced
intestinal injury. Recent adenovirus-mediated delivery of
SOCS-3 into the ankle joints of animals with arthritis
was shown to drastically reduce disease severity.119 Ad-
enovirus-mediated SOCS-3 delivery to the intestine
therefore holds promise for defining its role in the intes-
tine during experimentally induced inflammation, which
in turn would provide insights into whether SOCS-3
may be a useful future target for development of new
therapies for IBD.
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Cytokine Inducible SH2-Domain
Containing Proteins
CIS was discovered in a search for immediate-
early cytokine-responsive genes20 and shares the highest
sequence and structural homology with SOCS-2. CIS is
induced in response to many hematopoietic cytokines
such as IL-1, IL-6, IL-12, IL-13, LIF, G-colony stimu-
lating factor, thrombopoietin, IL-2, IL-3, EPO, but also
a number of nonhematopoietic cytokines such as GH,
leptin, and prolactin (Table 1). The mRNA induction
pattern of CIS is rapid and transient as for SOCS-1 and
SOCS-3, except there may be a second or more prolonged
phase of CIS induction in some systems.35 Initial in vitro
experiments showed that CIS was capable of inhibiting
EPO, IL-2, IL-3, GH, and prolactin signaling to various
degrees of effectiveness, but displayed a different mech-
anism of action compared with the other SOCS studied
to date. CIS requires receptor phosphorylation before it
can bind to cytokine receptors and its inhibitory effects
are JAK independent.20,120 Overexpression studies have
shown that CIS can bind to only one of 2 STAT5 binding
sites on the EPO receptor and inhibits only a proportion
of STAT5 activity. This had led to a concept that CIS
may compete with STAT5 for receptor docking
sites.120,121 This is supported by work examining the role
of CIS in GH signaling, which has revealed that CIS
inhibition of GH signaling is more complete at lower
levels of STAT5b expression.87 Because of the transient
nature of CIS mRNA expression it is an attractive hy-
pothesis that CIS may play a role in the suppression of
pulsatile GH-induced STAT5 activity that typifies GH
action in men in particular. CIS is capable of binding to
the C-terminal portion of the GH receptor that contains
STAT5 docking sites83,85 and can inhibit a proportion of
STAT5 activity. The use of the proteasomal degradation
blocker, MG132, has shown that CIS inhibition of GH
signaling involves a 2-step mechanism: the first is the
binding of CIS to STAT5 binding sites, and the second
is subsequent targeting of bound receptor complexes for
proteasomal-targeted destruction.87 This 2-step mecha-
nism may be crucial for the time-dependent inhibition of
GH signaling that is thought to cycle every 3–4 hours.
As with other SOCS, genetically modified mice were
created in an attempt to clarify the physiologic role of
CIS. CIS transgenic mice expressing high levels of CIS
via the -actin promoter have been produced and suffer
from a complex phenotype. This includes reduced body
weights in adult male and female mice, lower levels of
the GH-dependent protein MUP, and a failure to lactate
owing to defective terminal differentiation of the mam-
mary gland.122 These phenotypes are reminiscent of mice
lacking STAT5 and/or STAT5.123–125 CIS transgenic
mice also display a depletion in numbers of  T cells,
natural killer, and natural killer T cells, as well as some
inhibition of IL-2 induced by STAT5 activity in T cells.
Transgenic expression of CIS in CD4 T cells also
implicates CIS as a regulator of T-cell receptor–mediated
T-cell activation.126 Paradoxically, CIS-deficient animals
display no obvious phenotype to date.51,56 It also is
surprising that the CIS transgenic and knockout mice
display no abnormality in blood cell production given
the predicted importance of CIS in regulating EPO
function.20,120 At present, little is known about CIS
in the gastrointestinal tract except that it is expressed
(Miller et al., unpublished data, 2002)34 and may show
distinct patterns of regulation in lamina propria vs.
peripheral lymphocytes.74
Other SOCS Family Members
Relatively little is known about the functions of
the other SOCS family members including the signaling
systems they regulate. SOCS-4 mRNA is expressed in
human colonic mucosa.32 SOCS-5 mRNA is induced in
mouse liver 8–12 hours after injection of IL-6 and in-
hibits a proportion of IL-6–mediated M1 cell differen-
tiation,24,37 but a definitive role for this molecule is yet
to be discovered. SOCS-6 was recently found to bind to
the insulin receptor in an insulin-dependent manner in
which it inhibited activation of extracellular-signal–reg-
ulated kinase 1/2 and protein kinase B in vivo, as well as
IR-directed phosphorylation of insulin receptor sub-
strate-1 in vitro.127 This indicates a possible role of
SOCS-6 in insulin resistance. Recent studies revealed
that SOCS-6 binds to insulin receptor substrate-4, a
molecule important in insulin receptor signaling and
that SOCS-6/ mice are slightly growth retarded.128
SOCS-7 (also known as NAP-4) has been found to in-
teract with the SH3 domain of Nck, as well as binding
to Ash, phospholipase-C, and the epidermal growth
factor receptor in vitro.129 Whether these observations
reflect the physiologic function of this molecule is un-
known.
The functions of the SOCS-related proteins that con-
tain a SOCS box but no SH2 domain is obscure. A
number of them have been shown to interact with elon-
gin B and C through their SOCS box.27,28 Extensive
analysis of ankyrin repeats-1 transgenic and knockout
mice failed to define any hematopoietic role for this
protein despite strong expression in the hematopoietic
compartment.130 More recent work has found that Asb-2
is induced rapidly by all-trans retinoic acid, which acts
on retinoid receptors or retinoid X receptor binding
elements in the ankyrin repeats 2 promoter.131 Interest-
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ingly, chicken WD-40 repeats-1 (also called SwiP-1) is
induced by sonic hedgehog in somatic mesoderm explant
cultures and developing limb buds.132 Whether it plays
a negative role in sonic hedgehog signaling is yet to be
shown, but given the importance of sonic hedgehog in
intestinal development, this warrants further study.
Conclusions and Future
Implications
Numerous in vitro experiments have highlighted
the diverse role that CIS, SOCS-1, -2, and -3 proteins
may play in the negative regulation of cytokine signal-
ing. Information is beginning to emerge about SOCS-4,
-5, -6, and -7. The generation of genetically modified
mice has validated and assigned a number of the SOCS
members as key mediators of important physiologic pro-
cesses (Table 2). A detailed understanding of the bio-
chemical mechanisms of SOCS action is being generated.
Further molecular and gene modification studies will
help to confirm and extend the current models and
hypotheses and define what role SOCS proteins play in
specific gastrointestinal functions and diseases. The
emerging information indicates that these proteins may
be integral to appropriate and coordinated actions of
cytokines and growth factors in the gastrointestinal tract
and accessory organs. As shown in Figure 4, SOCS appear
likely to play key roles in cytokine or growth factor
action on multiple cell types in the gastrointestinal tract
and in multiple physiologic and pathophysiologic states.
A wealth of evidence suggests that SOCS will impact on
cytokine regulation of immune cell function or pheno-
type and are essential to appropriate termination of in-
flammation. In this regard, SOCS may be pivotal in
dictating whether acute inflammatory states persist to
become diseases of chronic inflammation (Figure 4).
Emerging evidence suggests a role of SOCS in intestinal
mesenchymal cells where inhibition of cytokine/growth
factor action by SOCS could help determine the balance
between normal repair or excessive cytokine responses
leading to fibrosis (Figure 4). In crypt epithelial cells,
SOCS may limit hyperproliferative responses associated
with renewal, repair, or regeneration of mucosal epithe-
lium. It remains to be established if these roles are
particularly important after mucosal damage by proin-
flammatory cytokines. SOCS also may play a key role in
normal crypt homeostasis or as tumor suppressors in the
intestine as appears to be the case for SOCS-1 in liver
(Figure 4). At present, these putative actions of SOCS in
the gastrointestinal tract are based largely on findings in
other systems and a number of challenges remain in fully
defining the roles of SOCS in the gut and other systems.
Their widespread expression in multiple cell types poses
Table 2. Summary of Genetic Modification Studies of SOCS Genes and Their Implications for Function
Protein Phenotype Implicated function
CIS
Knockout No phenotype Unknown, redundancy?




Knockout Die prenatally, multiple hematopietic abnormalities, liver necrosis,
macrophage organ infiltration
Controls sensitivity to IFN, possible T-cell
function/selection
Transgenic
DN transgenic Defective thymocyte development and perturbed homeostasis of T
cells




Low expressors have no overt phenotype, but are more susceptible to
DSS-induced colitis
Hyperactivation of STAT3 results in severe colitis,
infers SOCS-3 regulates intestinal inflammation
responses
Similar to SOCS-1, but less prolonged signaling disfunction and
disease progression
Regulates cytokine signaling, possibly by
interacting with E3 ubiquitin ligase
SOCS-2
Knockout Excessive growth, some elevated IGF-I mRNA, thicker skin, collagen
deposition, lower MUP
Regulation of GH and/or IGF-I pathways
SOCS-3
Knockout Embryonic lethal (E11-E13), erythrocytosis in abdominal organs
Placental insufficiency
Controls EPO signaling
Involved in placental development
Transgenic Embryonic lethal (E11-E13), erythronemia Controls EPO signaling
SOCS-6 Mild growth retardation Unknown
Knockout
ASB-1
Knockout No phenotype Unknown
Transgenic No phenotype Unknown
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a challenge in unraveling cell-specific actions. Derivation
of mice with cell-specific deletion of particular SOCS, for
example, using intestinal epithelial, immune, mesenchy-
mal cell, or hepatocyte-specific promoters, and the Cre/
Lox system has particular potential to elucidate the role
of individual SOCS proteins in the actions of particular
cytokines and growth factors on intestinal growth, in-
flammation, wound healing, fibrosis, and cancer. Better
definition of the cell-specific patterns of expression of
each SOCS family member and elucidation of the conse-
quences of expression of multiple SOCS in some cell
types or situations vs. predominance of one particular
SOCS in others also is desirable. This will require in vivo
localization studies in normal and diseased gastrointes-
tinal tissue and creative cross-breeding approaches to
derive genetically manipulated mice with cell-specific
alterations in multiple SOCS proteins.
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